NCT00669942 - Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

AIN457

AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

DRUG

Placebo

Placebo to AIN457

Trial Locations (24)

1200

Novartis Investigative Site, Brussels

2170

Novartis Investigative Site, Merksem

15006

Novartis Investigative Site, A Coruña

15706

Novartis Investigative Site, Santiago de Compostela

16635

Novartis Investigative Site, Duncansville

19002

Novartis Investigative Site, Guadalajara

32127

Novartis Investigative Site, Port Orange

33773

Novartis Investigative Site, Largo

34471

Novartis Investigative Site, Ocala

34684

Novartis Investigative Site, Palm Harbor

42431

Novartis Investigative Site, Madisonville

61231

Novartis Investigative Site, Bad Nauheim

63110

Novartis Investigative Site, St Louis

73103

Novartis Investigative Site, Oklahoma City

80336

Novartis Investigative Site, München

85724

Novartis Investigative Site, Tucson

91054

Novartis Investigative Site, Erlangen

97701

Novartis Investigative Site, Bend

119074

Novartis Investigative Site, Singapore

529889

Novartis Investigative Site, Singapore

36207-5710

Novartis Investigative Site, Anniston

68131-2197

Novartis Investigative Site, Omaha

1105 AZ

Novartis Investigative Site, Amsterdam

6525 GA

Novartis Investigative Site, Nijmegen